Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive
However, recent regulatory changes regarding compounded GLP-1 weight-loss medications have significantly impacted the industry
Following robust weight loss with SEMA and even more dramatic weight loss with RETA, we next sought to determine impacts on PDAC
If approved, Wegovy will be the first GLP-1 agent to treat MASH
doi: 10.3389/fopht.2025.1680042 Received 05 August 2025 Accepted 22 September 2025 Published 13 October 2025 Corrected 21 October 2025 Volume 5 - 2025 Edited by Kevin Schey, Vanderbilt University, United States Reviewed by Janice Walker, Thomas Jefferson University, United States
How long before I see weight loss results
